http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Fluidigm Provides Update on COVID-19 Impact and Preliminary Revenue Estimate for First Quarter 2020
-
Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1
-
Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results
-
Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring
-
Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference
-
Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018
-
Fluidigm Recognized as a Company to Watch in 2019
-
Fluidigm Announces Third Quarter 2018 Financial Results
-
Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development
-
Fluidigm (FLDM) Appoints Laura Clague to Board
-
Laura Clague Named to Fluidigm Board of Directors
-
Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System
-
Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD
-
Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
-
Fluidigm Introduces Single-Cell Total RNA Sequencing Applications for C1
-
Fluidigm (FLDM) Reports Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis
-
Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis
-
Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD
-
Fluidigm to Participate at Upcoming Investor Events in September
-
Fluidigm to Host 2nd Annual Imaging Mass Cytometry User Group Meeting
-
Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fluidigm Announces Second Quarter 2018 Financial Results
-
Fluidigm Introduces a Lower-Cost Workflow for Full-Length Single-Cell mRNA Sequencing on C1
-
Fluidigm Announces First Multimodal Single-Cell Application for the C1
-
Fluidigm Announces Conference Call and Webcast of Second Quarter 2018 Financial Results
-
David King Joins Fluidigm as Vice President, Research and Development, Genomics
-
Fluidigm and Genomenon to Offer Evidence-Based Genomic Panel Design Service
-
Fluidigm Releases Sample Identification Genotyping Panel for Translational and Clinical Research
-
Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fluidigm to Participate in Upcoming Investor Events
-
Fluidigm Announces First Quarter Financial Results and Operational Progress
-
Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations
-
Fluidigm to Report Q1 2018 Financial Results and Host Conference Call
-
Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical Research
-
Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System
-
Fluidigm Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Progress
-
Fluidigm to Report Q4 and Full Year 2017 Financial Results
-
Fluidigm Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Fluidigm Announces Third Quarter Financial Results and Operational Progress
-
Fluidigm Announces Agreement With the University of Zurich to Distribute histoCAT for Multiparameter Imaging Mass Cytometry Data Analysis
-
Fluidigm Introduces Imaging Mass Cytometry System for Highly Multiplexed Protein Detection in Tissues
-
Fluidigm to Report Q3 2017 Financial Results and Host Conference Call
-
Fluidigm to Unveil High-Parameter Tissue Imaging System
-
Fluidigm Licenses CFTR Next-Generation Sequencing Assay From Baylor Genetics for Use With the Juno System
-
Fluidigm Announces Second Quarter Financial Results and Operational Progress
-
Fluidigm Corporation Announces Termination of Tax Benefit Preservation Plan
-
Fluidigm and Ascendas Genomics Announce Strategic Partnership to Develop Microfluidic Molecular Diagnostics in China
-
Fluidigm to Report Q2 2017 Financial Results and Host Conference Call
-
Fluidigm (FLDM) Announces Immuno-Oncology Gene Expression Assay for Translational and Clinical Research

